Mounjaro leads India obesity drug sales as generic semaglutide gains traction post patent expiry - India Today
The demand for obesity treatment drugs in India is rising rapidly, with Mounjaro emerging as a leading choice among patients and healthcare providers. Originally developed for diabetes management, this medication has gained popularity due to its strong weight-loss results. At the same time, generic versions of semaglutide are entering the market, offering more affordable alternatives and increasing accessibility for a wider population. Doctors are observing a shift in treatment preferences as awareness about obesity-related health risks continues to grow. Pharmaceutical companies are also expanding their presence, sensing a major opportunity in this fast-growing segment. However, experts caution that these drugs should be used under proper medical supervision, as lifestyle changes remain essential for long-term results. Overall, India’s obesity drug market is evolving quickly, driven by innovation, affordability, and increasing health consciousness among consumers.
The Key points
- Mounjaro leads India’s fast-growing obesity drug market
- Initially developed for diabetes, now widely used for weight loss
- Generic semaglutide is gaining popularity due to lower cost
- Rising obesity cases are driving higher drug demand
- Increased awareness of health risks fuels treatment adoption
- Doctors report shifting patient preferences toward new therapies
- Pharma companies see strong growth potential in India
- Affordability is improving with entry of generic alternatives
- Medical supervision is essential for safe drug usage
- Lifestyle changes remain crucial alongside medication
Disclaimer: This preview includes title, image, and description automatically sourced from the original website (www.indiatoday.in) using publicly available metadata / OG tags. All rights, including copyright and content ownership, remain with the original publisher. If you are the content owner and wish to request removal, please contact us from your official email to no_reply@newspaperhunt.com.
